

# The Utility of ChatGPT in Diabetic Retinopathy Risk Assessment: A Comparative Study with Clinical Diagnosis [Response to Letter]

Keerthana Raghu<sup>1,\*</sup>, Tamilselvi S<sup>2,\*</sup>, Chitralekha S Devishamani<sup>1</sup>, Suchetha M<sup>2</sup>,  
Ramachandran Rajalakshmi<sup>3</sup>, Rajiv Raman<sup>1</sup>

<sup>1</sup>Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India; <sup>2</sup>Centre for Health Care Advancement, Innovation, and Research Department, Vellore Institute of Technology, Chennai, Tamil Nadu, India; <sup>3</sup>Department of Diabetology, Ophthalmology and Epidemiology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Chennai, Tamil Nadu, India

\*These authors contributed equally to this work

Correspondence: Rajiv Raman, Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India, Email [rajivpgraman@gmail.com](mailto:rajivpgraman@gmail.com)

## Dear editor

We are writing in response to Elanda Fikri's letter regarding our recently published article titled "The Utility of ChatGPT in Diabetic Retinopathy Risk Assessment: A Comparative Study with Clinical Diagnosis" in *Clinical Ophthalmology*.

Firstly, we wish to express our gratitude to Fikri for their insightful feedback on our study. We appreciate the recognition of our work in utilizing ChatGPT-4 for generating medical reports and evaluating its prediction accuracy against clinical diagnosis using anonymized data. The interest and discussion our study has sparked are both encouraging and invaluable.

Addressing the limitations pointed out by Fikri, we concur with the concerns regarding the use of a research version of ChatGPT. The potential for generating nonsensical or incorrect information due to training data and algorithmic limitations is a valid point. The current version of ChatGPT primarily acquires knowledge from publicly available texts and is not specifically trained for medical tasks, which limits its comprehensive understanding of complex medical scenarios.<sup>1</sup>

To enhance the capabilities of current Large Language Models (LLMs) like ChatGPT, further training with detailed knowledge of eye anatomy, physiology, and diseases is essential. Incorporating specialized ophthalmological literature and clinical guidelines into the training process can significantly transform LLMs into effective tools for ophthalmic applications. However, much of this specialized material remains publicly inaccessible, which poses a limitation to the scope of LLM training. This underscores the need for clinicians to critically review and verify the outputs against accurate and current medical information.<sup>2</sup>

Ethical considerations in healthcare research were paramount in our study. We adhered to strict ethical guidelines to ensure patient confidentiality and data privacy. Although ChatGPT is not yet fully HIPAA compliant, we implemented rigorous anonymization procedures to safeguard patient privacy. Any data utilized was thoroughly de-identified, making it impossible to trace back to individual patients. Nevertheless, the ethical concerns surrounding data privacy and the integration of LLMs like ChatGPT into clinical routines warrant careful consideration and must be addressed diligently.

Despite its current limitations, our study's use of ChatGPT allowed us to explore the potential of language models in predicting diabetic retinopathy risk based on clinical and biochemical parameters. This novel approach paves the way for future research. We align with your suggestions on the necessity for further optimization and are committed to enhancing the capabilities of ChatGPT through future studies. Collaborations with healthcare professionals, technology vendors, and researchers are crucial for improving the accuracy and reliability of these models.

Thank you for the opportunity to discuss our study further. We are committed to contributing to the advancement of medical knowledge and improving patient care through responsible AI usage.

## Disclosure

No conflicting relationship exists for any author in this communication.

## References

1. Nori H, King N, McKinney SM, Carignan D, Horvitz E. Capabilities of gpt-4 on medical challenge problems. *arXiv*. 2023. doi:10.48550/arXiv.2303.13375
2. Betzler BK, Chen H, Cheng CY, et al. Large language models and their impact in ophthalmology. *Lancet Digital Health*. 2023;5(12):e917–24. doi:10.1016/S2589-7500(23)00201-7

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Ophthalmology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Ophthalmology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Ophthalmology

Dovepress

### Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-ophthalmology-journal>

<https://doi.org/10.2147/OPTH.S461186>